Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2008

View Archived Issues

Recent Biogen Idec patents report novel antifibrotic agents

Novel antipsoriatic agents disclosed in recent Sunesis patents

New treatment options for sepsis described in recent Wyeth patent

PTH fusion protein more effective than PTH(1-34) as antiosteoporotic in preclinical studies

Phase III advanced melanoma study of Genasense cleared to continue

Betaseron to become available with thinnest needle in MS

FDA accepts for review Basilea's complete response ceftobiprole NDA approvable letter

FDA approves ProStrakan's Sancuso transdermal patch for CINV

NIAID awards phase I grant to SIGA for dengue antiviral program

CV Therapeutics grants Menarini exclusive rights to angina drug Ranexa in 68 countries

Xel successfully completes development of huperzine A transdermal patch for AD

Denosumab effective in preventing bone resorption and increases BMD

Combination of AVE-1642 and other agents increases activity in hepatocellular carcinoma cells

Novel small ALDH2 activator protects the heart against ischemic damage

BT-201 slows osteoarthritis progression in rat model

FDA grants approval to Rexahn to initiate phase II trial of Serdaxin in MDD

Calando opens enrollment in phase II IT-101 study in ovarian cancer

Daiichi Sankyo files sNDA for Azor as initial therapy for hypertension

European Commission grants orphan drug designation to Alseres' Cethrin

Merck presents update on Erbitux data in colorectal cancer and lung cancer

Cadence to report results from CLIRS phase III clinical trial in first quarter of 2009

Cequent meets second milestone in option agreement with Novartis Option Fund in IBD

Recent efficacy and safety results presented from a phase II NX-1207 study in LUTS-BPH

Proteologics licenses three cancer programs to Teva

FDA issues complete response to Cephalon's sNDA for Fentora in noncancer breakthrough pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...